기본 정보
- CAS
200815-49-2- 표준 SMILES
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1.O=C(O)[C@H](O)[C@@H](O)C(=O)O- InChIKey
FCSXYHUNDAXDRH-OKMNHOJOSA-N- 분자식
- C23H30N2O10
- 평균 분자량
- 494.5 g/mol
- 단동위원소 질량
- 494.19004516
개요
Arformoterol Tartrate is the tartrate salt of arformoterol, the (R,R)-enantiomer of formoterol and a long-acting beta-2 adrenergic agonist with bronchodilator activity. Arformoterol selectively binds to and activates beta-2 adrenergic receptors in bronchiolar smooth muscle, thereby causing stimulation of adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased intracellular cAMP levels cause relaxation of bronchial smooth muscle and lead to an inhibition of release of inflammatory mediators from mast cells. This may eventually lead to an improvement of airway function.
이름 및 식별자
- 우선 이름
- Arformoterol Tartrate
- IUPAC
- (2R,3R)-2,3-dihydroxybutanedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide
- 현지명
- 아르포모테롤타르트레이트
- 영어명
- Arformoterol tartrate
- 분자식
- C19H24N2O4.C4H6O6
- 분자량
- 494.49
이름 및 동의어
Arformoterol tartrate200815-49-2Brovana(R,R)-Arformoterol tartrateUNII-5P8VJ2I2355P8VJ2I235DTXSID80173903(-)-N-(2-Hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)formamide hydrogen (2R,3R)-2,3-dihydroxybutanedioate (salt)Formamide, N-(2-hydroxy-5-((1R)-1-hydroxy-2-(((1R)-2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt)ARFORMOTEROL TARTRATE (MART.)ARFORMOTEROL TARTRATE [MART.]Formoterol r,r-form l-tartrate
이름 더 보기
아르포모테롤타르트레이트200-589-5Aphmote tartrateAforterol tartrateR,R-Form L-tartrateAfromoterol tartrateArformoterol L-tartrate(R,R)-Formoterol tartrate(R,R)-ForMoterol-L-(+)-TartrateFormoterol Impurity 23 Tartrate
RefChem:56496Arformoterol Tartrate InhalationDTXCID6096394Arformoterol Tartrate Inhalation SolutionFormamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)Arformoterol Tartrate [USAN](2R,3R)-2,3-dihydroxybutanedioic acid;N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamideArformoterol tartrate (USAN)
물성
구조 계산 물성
- 극성 표면적
- 206 Ų
- 수소 결합 공여자 수
- 8
- 수소 결합 수용자 수
- 11
- 회전 가능 결합 수
- 11
- 무거운 원자 수
- 35
- 형식 전하
- 0
- 복잡도
- 521
실험 및 물리화학적 성질
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
물리화학적 성질
- 녹는점
- 184 ° · 184°
- 저장 조건
- Refrigerator, Under Inert Atmosphere
- 용해도
- DMSO(약간 용해됨, 초음파 처리), 메탄올(약간 용해됨, 가열, 초음파 처리)
- 물리적 상태
- 고체
- 색상
- 흰색에서 옅은 갈색까지
- InChIKey
- FCSXYHUNDAXDRH-LFJODZMVNA-N
- SMILES
- C1(NC=O)=C(C=CC([C@@H](O)CN[C@H](C)CC2C=CC(=CC=2)OC)=C1)O.[C@@H]([C@H](C(O)=O)O)(C(O)=O)O |&1:8,12,25,26,r|
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
GHS 분류
GHS Classification
Danger
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P233, P260, P261, P264, P264+P265, P270, P271, P273, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P316, P318, P319, P320, P321, P330, P332+P317, P337+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
유해성 정보
Hazard Classes and CategoriesAcute Tox. 4 (100%)
안전 데이터
- 신호 어
- Danger
- 유해·위험 문구
- 암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302
화학 및 산업
약리 정보
FDA Pharmacological Classification
ARFORMOTEROL TARTRATE
Adrenergic beta2-Agonists [MoA]; beta2-Adrenergic Agonist [EPC]
ARFORMOTEROL TARTRATE INHALATION
beta2-Adrenergic Agonist [EPC]; Adrenergic beta2-Agonists [MoA]
ARFORMOTEROL TARTRATE INHALATION SOLUTION
beta2-Adrenergic Agonist [EPC]; Adrenergic beta2-Agonists [MoA]
응용 분야
개요Sepracor’s Brovana®, a nebulized long acting bronchodilator, was launched in the U.S. in April 2007. The β2- adrenoceptor agonist is indicated for the twice-daily, longtermmaintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. It is the first long-acting nebulized bronchodilator approved by the FDA for this indication.
용도Anti-asthmatic and bronchodilator.
공급사100 곳
苏州道澜生物医药科技有限公司15952404857 · [email protected]
Shandong chuangyingchemical Co., Ltd.18853181302 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
艾吉析科技（上海）有限公司17717235263 · [email protected]
郑州汇聚化工有限公司0371-53399770 18037166334 · [email protected]
HubeiwidelychemicaltechnologyCo.,Ltd18627774460 · [email protected]
관련 반응
4건
화합물 노트
불러오는 중…